Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Saturday, July 2, 2011

MSAA's new mobile phone application


My MS Manager

Welcome to My MS Manager - MSAA's new mobile phone application, provided free of charge to individuals with multiple sclerosis (MS) or their care partner to use on their iPhone, iPad or iPod touch. Developed in conjunction with Ringful Health, this first-of-its kind app for MS offers individuals a convenient and effective tool to manage the ever-changing course of the disease.
As a member of the MS community, My MS Manager allows you to input and store:
  • Comprehensive medical records
  • Contact information of your healthcare team
  • Descriptions of MS flare-ups, tracking their duration, frequency and intensity
  • Informationon side effects and effective treatment strategies 
  • Important details essential to staying one step ahead of your MS
Once you begin using My MS Manager, reports can be generated utilizing the activities and occurrences logged on your phone. These reports can also be shared with doctors and other members of your healthcare team via email updates and secure online access. Other features of the app include an always up-to-date feed of MS-related news and links to MS resources, including MSAA events and contact info and a Google Map-powered locator to find nearby emergency care, physicians, or hospitals instantly from your mobile device.
My MS Manager is now available in the Apple App Store. 
Download My MS Manager today!



=====================================================================
.
**************************************************************** 
Know somebody affected by Multiple Sclerosis?
Remain CURRENT with Multiple Sclerosis news & information 
 when registered at the  MS Views and News  website
.Weekly e-Newsletter now reaching (87) Countries. .
***************************************************************************************
Help STUART  to Educate:  Please donate   
- all contributions are tax deductible - 
We are a 501c3 - Not for Profit Charity
.
"Providing You with 'MS Views and News'is what we do"
***************************************************************************************
.
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

Friday, July 1, 2011

Laquinimod: The next oral agent for multiple sclerosis?


Key point: According to a Phase III trial of the once-daily, investigational immunomodulatory laquinimod, this agent significantly reduced annualized relapse rate, risk of confirmed disability progression, and progression of brain atrophy, and was well-tolerated with a placebo-like adverse event profile.


.
**************************************************************** 
Know somebody affected by Multiple Sclerosis?
Ask them to remain CURRENT with Multiple Sclerosis news & information 
 when registered at the  MS Views and News  website
.Weekly e-Newsletter now reaching (87) Countries. .
***************************************************************************************
Help STUART  to Educate:  Please donate   
- all contributions are tax deductible - 
We are a 501c3 - Not for Profit Charity
.
"Providing You with 'MS Views and News'is what we do"
***************************************************************************************
.
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

Thursday, June 30, 2011

Low-dose naltrexone – a research blog for patients and caregivers

Visit the research blog on Low-dose naltrexone. USE this blog to explore both the experience of people who have used the medication but also barriers to accessing the medication.
Over the course of the last few years there has been an increasing about of discussion regarding the use of Low-dose naltrexone (LDN) to treat various medical conditions such as multiple sclerosis,Crohn’s disease and fibromyalgia.  Recent research from the University of Freiburg has indicated that LDN may also be useful in treating disassociation which can be associated with borderline personality disorders and post-traumatic stress disorder (PTSD).
LDN is a controversial product not least because it was developed as a way of treating heroin addiction.  For MS,for example,the jury is still out on its effectiveness.  But that does not stop many patients advocating its use! That is why we there is interest in the opinions of people who have used LDN.
Of particular interest are the following questions:-
a)    Have you ever used LDN and for what condition was it prescribed?
b)    How effective was LDN for treating your condition?
c)     How easy was it for you to be prescribed LDN?  Were you ever turned down for it?
d)    How did you find out about LDN?
e)    What sources of information would you recommend to others regarding LDN?
f)     Did you ever consider using LDN which had not been prescribed by a physician?
Please do treat these questions as a guide we would love to have any comments you might make!
To take part in the research blog please click here, taking you to the PATIENT EXPERIENCE  page where you can add your comments in the box provided. Alternatively you can reply to the comments and experiences of others.


.
**************************************************************** 
Remain CURRENT with Multiple Sclerosis news & information 
 when registered at the  MS Views and News  website
.Weekly e-Newsletter now reaching (87) Countries. .
***************************************************************************************
Help STUART  to Educate:  Please donate   
- all contributions are tax deductible - 
We are a 501c3 - Not for Profit Charity
.
"Providing You with 'MS Views and News'is what we do"
***************************************************************************************
.
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

Wednesday, June 29, 2011

Unique gMS blood tests, leads 'Glycominds' to receive Japanese nod for its patent of diagnostic process of multiple sclerosis


Israel - Tuesday, June 28, 2011
Glycominds, which develops a unique technology and provides via it CLIA certified clinical laboratory groundbreaking services for early detection and management of Multiple Sclerosis (MS), reported that it has received approval from the Japanese Patent Office for the registration of its application for a patent for its main process for early diagnosis and management of MS.

The approval of this Patent further strengthens the intellectual property of Glycominds and is an expansion of the extensive patent protection held by the company, which has more than 100 issued and registered patents. Glycominds now intends to examine possible entry into the Japanese market, which is considered the second largest market in the medical field.

Glycominds’ CLIA laboratory is processing the company's unique gMS blood tests, that dramatically shorten the time it takes to diagnose MS, and predict the course of progression of the disease. This technology allows the neurologist better treatment decision. Currently there are no competing blood tests for MS.  The Company estimates the market potential for MS tests at about 1 billion dollars.

Glycominds recently reported the successful results of a clinical study of its prognostic test, the gMSPro CDMS. This test predicts events of clinical relapses in patients suspected with Multiple Sclerosis. The clinical study was held at the centre for Multiple Sclerosis of Catalonia, at the University Hospital Vall d'Hebron in Barcelona Spain, with a leading research group, led by Professor Xavier Montalban and Dr Mar Tintoré.

The gMSPro CDMS is the third test being developed by the Company. The two other tests: the gMSDx for early diagnosis of MS, and the gMSPro EDSS to predict the likelihood for rapid progression and accumulation of disabilities.

Dr Avinoam Dukler, CEO and president of Glycominds, said: "I am pleased that we have received the patent approval in Japan, which is an additional evidence of the technological innovation and the unique knowledge that we have developed at Glycominds. This approval is important and also supports the continued development of additional markets in the future for the company".

Glycominds, a molecular diagnostics company, develops and commercializes autoimmune and chronic inflammatory disease management tools and services with a distinctive focus on the Multiple Sclerosis market.

.
**************************************************************** 
Know somebody affected by Multiple Sclerosis?
Ask them to remain CURRENT with Multiple Sclerosis news & information 
 when registered at the  MS Views and News  website
.Weekly e-Newsletter now reaching (87) Countries. .
***************************************************************************************
Help STUART  to Educate:  Please donate   
- all contributions are tax deductible - 
We are a 501c3 - Not for Profit Charity
.
"Providing You with 'MS Views and News'is what we do"
***************************************************************************************
.
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.